Time to Initiated Antitumor Therapy for Tumor Patients With COVID19 Infection
NCT ID: NCT06006845
Last Updated: 2023-08-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2022-12-01
2024-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases adverse events related to antitumor therapy.
* Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases risk of re-infection of COVID-19.
* How initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 affects QoL of tumor patients
Participants will be asked to answer the question about:
* the severity and duration of COVID-19 symptoms
* the date of diagnosis of COVID-19
* the date of negative nucleic acid test
* the QoL of life before infection with COVID-19, during infection of COVID-19, after nucleic acid test negativity and receiving antitumor therapy
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor
NCT04894682
Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
NCT07052669
To Explore the Protective Effect of SARS-CoV-2 Vaccination on Cancer Patients Infected With SARS-CoV-2
NCT05774171
A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma
NCT07062484
Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer
NCT06861712
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Tumor patients infected with COVID-19
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* COVID-19 was confirmed by antigen testing or nucleic acid testing.
* Tumor was confirmed by pathology.
* Patients received systemic antitumor therapy after infected with COVID-19.
Exclusion Criteria
* Tumor was not confirmed by pathology
* Patients did not receive systemic antitumor therapy
* Patients died before receiving systemic antitumor therapy
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Seventh Affiliated Hospital of Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wang Bo
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bo Wang
Role: PRINCIPAL_INVESTIGATOR
The Seventh Affiliated Hospital of Sun Yat-sen University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seventh Affiliated Hospital, Sun Yat-sen University
Shenzhen, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
pan-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.